Navepegritide (TransCon CNP)
Achondroplasia
Phase 2Met primary objective (May 2023)
Key Facts
Indication
Achondroplasia
Phase
Phase 2
Status
Met primary objective (May 2023)
Company
About VISEN Pharmaceuticals
A China-focused biopharma company developing long-acting endocrine therapies using TransCon technology.
View full company profileTherapeutic Areas
Other Achondroplasia Drugs
| Drug | Company | Phase |
|---|---|---|
| Infigratinib | BridgeBio Pharma | Phase 3 |
| VOXZOGO (vosoritide) | BioMarin Pharmaceutical | Approved/Marketed |